When will the CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER patents expire, and when will CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Samson Medcl	CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER	cefepime hydrochloride	POWDER;INTRAVENOUS	209408-001	Aug 21, 2018		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Cefepime hydrochloride in plastic container products present a mature but stable market segment within the cephalosporin antibiotic class. Key investment considerations include patent expiration timelines, generic competition, and the evolving landscape of antibiotic stewardship and regulatory scrutiny.

What is the Current Patent Status for Cefepime Hydrochloride?

The fundamental patent for cefepime, the active pharmaceutical ingredient, has long expired. The original composition of matter patent for cefepime expired in the United States in 2003 [1]. Subsequent patents related to specific manufacturing processes or formulations may have also expired or are nearing expiration. The primary focus for investment in this area shifts from novel patent protection to the intellectual property surrounding drug delivery systems, such as specific plastic container designs or formulations that offer improved stability, ease of use, or reduced risk of contamination. However, these latter-stage innovations are less likely to command broad market exclusivity compared to original composition of matter patents.

What is the Competitive Landscape for Cefepime Hydrochloride in Plastic Containers?

The competitive landscape is characterized by a significant number of generic manufacturers. Cefepime hydrochloride is available in various dosage forms, including powder for injection, which is reconstituted before administration. The plastic container format is a common delivery method for ready-to-use or easily reconstituted injectable drugs, aimed at reducing preparation errors and enhancing convenience in clinical settings.

Key players in the generic cefepime market include:

Teva Pharmaceuticals: A major global generic pharmaceutical company.
Viatris (formerly Mylan and Pfizer's Upjohn): Another significant player in the generics space.
Fresenius Kabi: Known for its portfolio of generic injectable drugs and drug-delivery systems.
Hikma Pharmaceuticals: A multinational pharmaceutical group with a strong presence in generics.
Eagle Pharmaceuticals: While historically focused on proprietary drug delivery technologies, they may compete in specific segments.

The market is highly price-sensitive due to the prevalence of generics. Differentiation in the plastic container segment often centers on:

Container technology: Features like pre-filled syringes, bags with enhanced stability, or novel stopper designs to prevent leakage or contamination.
Manufacturing efficiency: Ability to produce at scale with competitive cost structures.
Regulatory compliance: Adherence to stringent FDA and EMA manufacturing standards.

The availability of cefepime in plastic containers is a response to the demand for improved drug administration safety and efficiency in hospitals and clinics. These containers aim to minimize the risk of needlestick injuries, particulate contamination, and preparation errors associated with traditional vials and separate reconstitution steps.

What are the Market Size and Growth Projections for Cefepime Hydrochloride?

The market for cefepime hydrochloride, as a broad-spectrum cephalosporin, remains substantial due to its established efficacy against a wide range of Gram-negative and Gram-positive bacteria. It is a critical antibiotic for treating moderate to severe infections, including pneumonia, complicated urinary tract infections, skin and soft tissue infections, and febrile neutropenia.

Estimates for the global cefepime market size vary, but it is generally considered a multi-hundred-million-dollar market annually. For instance, market research reports from 2023 and early 2024 indicate a global market value ranging from $400 million to $600 million USD [2, 3].

Growth projections are typically modest, reflecting the drug's maturity and the rise of newer antibiotic classes and therapeutic strategies. Expected Compound Annual Growth Rates (CAGRs) for the overall cefepime market are in the low single digits, generally between 2% and 4% [3]. The segment for cefepime in plastic containers might see slightly higher growth driven by the adoption of pre-mixed or ready-to-use formulations that enhance clinical efficiency and safety.

Factors influencing market growth include:

Prevalence of bacterial infections: Continued incidence of serious bacterial infections requiring broad-spectrum antibiotic therapy.
Hospital formulary adoption: Cefepime's inclusion in hospital formularies due to its efficacy and cost-effectiveness.
Antibiotic stewardship programs: While these programs aim to curb overuse, they also highlight the importance of effective agents like cefepime when indicated.
Adoption of advanced drug delivery systems: Increasing preference for pre-filled or ready-to-use injectable formats in healthcare settings.

Conversely, growth can be constrained by:

Antibiotic resistance: The emergence of resistance to cephalosporins, leading to the need for alternative or combination therapies.
Development of novel antibiotics: Newer agents with broader spectra or different mechanisms of action.
Regulatory pressures: Increased scrutiny on antibiotic use and manufacturing standards.

What are the Regulatory Considerations for Cefepime Hydrochloride in Plastic Containers?

Regulatory compliance is paramount for any pharmaceutical product, especially injectables. For cefepime hydrochloride in plastic containers, regulatory considerations span manufacturing, quality control, packaging, and labeling.

Key regulatory bodies and their requirements include:

U.S. Food and Drug Administration (FDA):
- Abbreviated New Drug Applications (ANDAs): Generic manufacturers must demonstrate bioequivalence to the reference listed drug.
- Current Good Manufacturing Practices (cGMP): Strict adherence to regulations governing facility design, equipment, processes, and quality control to ensure product safety, efficacy, and purity.
- Container Closure Integrity: Specific testing and validation requirements for plastic containers to ensure sterility, prevent leachables, and maintain drug stability throughout its shelf life. The choice of plastic material (e.g., polypropylene, polyethylene) and its interaction with the drug product are critical.
- Drug Master Files (DMFs): Manufacturers of active pharmaceutical ingredients (APIs) and excipients must maintain DMFs detailing their manufacturing processes and quality controls.
- Labeling requirements: Precise information regarding dosage, administration, warnings, and storage conditions.
European Medicines Agency (EMA) and National Competent Authorities:
- Marketing Authorisation Applications (MAAs): Similar to ANDAs, but with specific European requirements.
- EU GMP Guidelines: Comprehensive guidelines for pharmaceutical manufacturing.
- Pharmacovigilance: Post-market surveillance for adverse events.
Other International Regulatory Bodies: Adherence to respective national regulations for drug approval and manufacturing.

Specific to plastic containers:

USP <87> Biological Reactivity Tests, In Vitro: Requirements for biocompatibility of materials.
USP <661> Plastic Packaging Systems and Their Materials of Construction: Standards for plastic materials used in packaging.
USP <71> Sterility Tests: Essential for injectable products.
USP <85> Bacterial Endotoxins Test: Critical for injectable pharmaceuticals.

The selection and validation of plastic materials are crucial to prevent drug degradation, extractables that could be toxic, and leachables that might affect the drug's performance. The entire manufacturing process, from API sourcing to final product packaging, must be meticulously documented and validated to meet these stringent requirements.

What are the Investment Opportunities and Risks Associated with Cefepime Hydrochloride in Plastic Containers?

Investment in cefepime hydrochloride in plastic containers is primarily within the generic pharmaceutical sector, focusing on established products with proven clinical utility.

Investment Opportunities:

Market Stability: Cefepime remains a frontline antibiotic for serious infections, ensuring consistent demand. The plastic container format enhances its attractiveness for clinical use.
Cost-Effective Treatment: Generics offer significant cost savings compared to branded alternatives, making them attractive for healthcare systems, especially in price-sensitive markets.
Operational Efficiency: Companies with streamlined manufacturing processes and robust supply chain management can achieve competitive cost structures.
Geographic Expansion: Opportunities exist in emerging markets where access to advanced drug delivery systems and broad-spectrum antibiotics is growing.
API Manufacturing: For companies with strong API production capabilities, supplying cefepime hydrochloride to generic formulators can be a profitable venture.
Strategic Partnerships: Collaborations with healthcare providers or distributors to ensure consistent supply and adoption.

Investment Risks:

Intense Generic Competition: A crowded generic market leads to significant pricing pressure and reduced profit margins.
Antibiotic Resistance: The increasing prevalence of multidrug-resistant organisms can reduce the clinical utility of older antibiotics like cefepime, potentially impacting demand over the long term.
Regulatory Hurdles: Delays or failures in regulatory approval processes, or stringent new requirements, can impact market entry and profitability.
Supply Chain Disruptions: Reliance on global supply chains for APIs and manufacturing components can expose companies to risks from geopolitical events, natural disasters, or trade disputes.
Technological Obsolescence: While cefepime is established, the development of novel antibiotics or alternative treatments could eventually displace it.
Stewardship Programs: Aggressive antibiotic stewardship efforts could lead to reduced prescribing of broad-spectrum agents when not strictly indicated, impacting volume.
Patent Challenges for Advanced Formulations: While the core patent is expired, any patents on proprietary plastic container designs or advanced formulations could be subject to litigation.

For investors, the opportunity lies in identifying manufacturers with strong operational execution, cost advantages, and established distribution networks in key markets. The plastic container aspect offers a niche where innovation in delivery can still provide a competitive edge, provided it is cost-effective and meets clinical needs.

Key Takeaways

Cefepime hydrochloride in plastic containers represents a mature segment within the antibiotic market. Investment attractiveness hinges on operational efficiency, cost competitiveness, and strategic market positioning rather than novel patent protection. The market benefits from the established efficacy of cefepime, while facing headwinds from generic competition and the long-term threat of antibiotic resistance. Regulatory compliance, particularly concerning cGMP and container closure integrity, is critical. Opportunities exist for manufacturers capable of efficient production and reliable supply, with potential for growth in markets adopting advanced drug delivery systems. Risks are primarily driven by pricing pressures, evolving resistance patterns, and potential supply chain vulnerabilities.

FAQs

What is the primary advantage of cefepime hydrochloride in plastic containers compared to traditional vial formulations?

The primary advantages are enhanced patient safety and clinical efficiency. Plastic containers often come pre-filled or are designed for simpler reconstitution, reducing preparation time, minimizing the risk of needlestick injuries, and lowering the potential for microbial contamination or particulate introduction during compounding.

How does antibiotic resistance impact the long-term investment outlook for cefepime hydrochloride?

Increasing antibiotic resistance to cephalosporins can lead to a decline in the clinical utility and demand for cefepime, potentially impacting its market share and growth prospects. This necessitates a shift towards newer agents or combination therapies in some treatment scenarios.

Are there any remaining patents that could significantly impact the market for cefepime hydrochloride in plastic containers?

While the original composition of matter patent for cefepime has expired, patents related to specific manufacturing processes, unique formulations, or proprietary plastic container designs and delivery mechanisms could still exist. These may offer limited protection or create niche market advantages.

What are the most significant regulatory challenges faced by manufacturers of cefepime hydrochloride in plastic containers?

Manufacturers face stringent requirements for cGMP compliance, bioequivalence demonstration for generics (ANDA submissions), and rigorous validation of container closure systems to ensure sterility, stability, and prevention of leachables. Continuous adherence to evolving regulatory standards is essential.

How does the cost structure of producing cefepime hydrochloride in plastic containers compare to traditional vial formulations?

The cost structure can vary. While plastic containers might have higher initial material costs, the potential for automated filling processes, reduced need for complex vial stoppers, and streamlined preparation in clinical settings can lead to overall cost efficiencies in the supply chain and administration. However, the competitive generic market often forces manufacturers to optimize every aspect of their cost base.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website] (Note: Specific patent expiration dates are often dynamic and best confirmed through direct searches on the FDA's Orange Book or USPTO databases.)

[2] Global Market Insights. (2023). Cefepime Market Size, Share & Industry Analysis Report By Product Type (Generic, Branded), By Dosage Form (Powder for Injection, Injection), By Application (Pneumonia, UTI, Skin Infection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), And Regional Forecasts, 2023 – 2030.

[3] Grand View Research. (2024). Cefepime Market Size, Share & Trends Analysis Report By Product (Generic, Branded), By Dosage Form (Powder for Injection, Injection), By Application (Pneumonia, UTI, Skin Infection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2024 – 2030.

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Cefepime Hydrochloride In Plastic Container, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cefepime Hydrochloride In Plastic Container

AI Deep Research

Questions you can ask:

Summary for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

US Patents and Regulatory Information for CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

Cefepime Hydrochloride in Plastic Container: Investment and Market Fundamentals